View Author
patient treatment hepatitis study hepatitis c interferon ribavirin genotype peginterferon therapy group virus response infection narlaprevir ana 773 level jtk -652 hepatitis c patients peginterferon alfa -2b -652 virological response activity decline combination effect baseline concentration hepatitis c virus phase period inhibitor trial dosing hcv rna virological liver safety hepatology ritonavir hepg 2 cells pharmacokinetic figure protease non-responder placebo administration svr rates peginterferon alfa -2a plasma randomized induction value serum interferon alfa -2b hcv genotype 1 interferon alfa gastroenterology regimen 48 weeks cohort hcv infection week 4 pseudotype 24 weeks genotype 1 telaprevir activation sample agonist event hepatitis c infection treatment duration result hcv-rna table duration outcome 72 weeks genotype 2
6 Most Recent Publications
|
Continuous interferon-α,2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients
(Article)
Roomer, R. Bergmann, J.F. Boonstra, A. Hansen, B.E. Haagmans, B.L. Kwadijk-De Gijsel, S. Vuuren, A.J. van Knegt, R.J. de Janssen, H.L.A. |
2012-06-05
|
|
Evolving drug therapies for chronic hepatitis C: Immunomodulation and beyond
(Doctoral Thesis)
Bergmann, J.F. |
2011-11-23
|
|
Randomised clinical trial: Anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV
(Article)
Bergmann, J.F. Bruijne, J. Rahimy, M. Appleman, J.R. Freddo, J.L. Janssen, H.L.A. Reesink, H.W. Hotho, D.M. Knegt, R.J. de Boonstra, A. Weegink, C.J. Vliet, A.A. Wetering, J. van de Fletcher, S.P. Bauman, L.A. |
2011-08-01
|
|
Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients
(Article)
Bruijne, J. Bergmann, J.F. Lier, J.J. Vliet, A.A. Janssen, H.L.A. Knegt, R.J. de Reesink, H.W. Weegink, C.J. Molenkamp, R. Schinkel, J. Tong, X. Li, J. Treitel, M.A. Hughes, E.A. |
2010-11-01
|
|
Safety and antiviral activity of JTK-652: A novel HCV infection inhibitor
(Article)
Bruijne, J. Bergmann, J.F. Schinkel, J. Reesink, H.W. Janssen, H.L.A. Weegink, C.J. Nieuwkerk, C.M.J. van Knegt, R.J. de Komoda, Y. Rooij, J.J.V.D.W. de Vliet, A.A. Jansen, P.L.M. Molenkamp, R. |
2010-10-08
|
|
γ-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-α-2b in chronic hepatitis C non-responders
(Article)
Bergmann, J.F. Vrolijk, J.M. Janssen, H.L.A. Schalm, S.W. Knegt, R.J. de Schaar, P.J. van der Vroom, B. Hoek, B. van Sluys Veer, A. van der Vries, R.A. de Verhey, E. Hansen, B.E. Brouwer, J.T. |
2007-11-01
|
